Investing.com - Celldex Therapeutics (NASDAQ: CLDX) reported first quarter EPS of $-0.62, worse than the analyst estimate of $-0.62. Revenue for the quarter came in at $967K versus the consensus estimate of $650K.
Celldex Therapeutics's stock price closed at $31.49. It is down -31.68% in the last 3 months and up 3.79% in the last 12 months.
Celldex Therapeutics saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Celldex Therapeutics's stock price’s past reactions to earnings here.
According to InvestingPro, Celldex Therapeutics's Financial Health score is "weak performance".
Check out Celldex Therapeutics's recent earnings performance, and Celldex Therapeutics's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar